{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-196507","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.636906+00:00","generated_at":"2026-05-31T11:09:55.245682+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Disc Medicine Q2 net loss $26.4M; cash $500.9M; positive EHA data across pipeline","bullets":["Net loss of $26.4M for Q2 2024 vs $15.9M in Q2 2023; R&D expenses rose to $23.5M.","Cash, cash equivalents & marketable securities of $500.9M as of June 30, 2024; raised $178M in June offering.","Presented positive data for bitopertin (EPP), DISC-0974 (anemia of MF), and DISC-3405 (hepcidin) at EHA 2024.","Expects regulatory interactions for bitopertin and DISC-0974 in H2 2024; DISC-3405 MAD data also expected in H2.","Cash runway expected to fund operations well into 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-196507","json":"https://secwatch.observer/filing/0001193125-24-196507.json","markdown":"https://secwatch.observer/filing/0001193125-24-196507.md","text":"https://secwatch.observer/filing/0001193125-24-196507.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000119312524196507/0001193125-24-196507-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000119312524196507/d802145d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:09:55.245682+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}